A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies (COVIMAB)

Assistance Publique - Hôpitaux de Paris

Status: Enrolling

Conditions: Immunocompromised Patients

Treatments: Other: Data collection

Study type: Observational

Funder types: Other

Identifiers

NCT05439044

APHP220631

Details and patient eligibility

About

Absence of anti-SARS-CoV-2 vaccine response or insufficient vaccine response may occur in immunocompromised patients. Being at high risk of a severe form of Covid-19, they may be eligible to receive recombinant anti-SARS-CoV-2 monoclonal antibodies (mAbs). This study aims to describe patients who received anti-SARS-CoV-2 mAbs, in prophylaxis and/or curative of covid-19, and to analyze the hospitalization and mortality rates. This study is multicentric on all the university hospitals of Paris (AP-HP).

Enrollment: 4,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult ≥ 18 years old
• Patients who received at least one administration of the following therapies: casirivimab-imdevimab, bamlanivimab-etesevimab, tixagevimab-cilgavimab, regdanvimab, sotrovimab or adintrevimab

Exclusion criteria

• Patients opposed to the collection of their personal data

Trial design

4,000 participants in 1 patient group

Patients who have received an anti-SARS-CoV-2 monoclonal antibody

Description:

Patients who have received an anti-SARS-CoV-2 monoclonal antibody, either prophylactically or curatively.

Treatment:

Other: Data collection